Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Total Liabilities
Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) has total liabilities worth CN¥477.34 Million CNY (≈ $69.85 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Zhuhai Sailong Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Zhuhai Sailong Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Zhuhai Sailong Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhuhai Sailong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mydas Real Estate Investments Ltd
TA:MYDS
|
Israel | ILA174.35 Million |
|
CWG Holdings Bhd
KLSE:9423
|
Malaysia | RM40.70 Million |
|
Maming Enam Sembilan Mineral Tbk PT
JK:AKSI
|
Indonesia | Rp131.72 Billion |
|
Encorp Bhd
KLSE:6076
|
Malaysia | RM598.07 Million |
|
B.A.G Films and Media Limited
NSE:BAGFILMS
|
India | Rs1.95 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Redcastle Resources Ltd
AU:RC1
|
Australia | AU$195.60K |
|
Atlas Menkul Kiymetler Yatirim Ortakligi AS
IS:ATLAS
|
Turkey | TL2.37 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002898 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhuhai Sailong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total liabilities of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥447.95 Million ≈ $65.55 Million |
+44.99% |
| 2024-12-31 | CN¥308.95 Million ≈ $45.21 Million |
+11.15% |
| 2023-12-31 | CN¥277.96 Million ≈ $40.67 Million |
-13.58% |
| 2022-12-31 | CN¥321.64 Million ≈ $47.07 Million |
+0.79% |
| 2021-12-31 | CN¥319.12 Million ≈ $46.70 Million |
+40.61% |
| 2020-12-31 | CN¥226.96 Million ≈ $33.21 Million |
+28.26% |
| 2019-12-31 | CN¥176.95 Million ≈ $25.89 Million |
+91.71% |
| 2018-12-31 | CN¥92.30 Million ≈ $13.51 Million |
-4.35% |
| 2017-12-31 | CN¥96.50 Million ≈ $14.12 Million |
+88.43% |
| 2016-12-31 | CN¥51.21 Million ≈ $7.49 Million |
-0.63% |
| 2015-12-31 | CN¥51.53 Million ≈ $7.54 Million |
+5.32% |
| 2014-12-31 | CN¥48.93 Million ≈ $7.16 Million |
-34.27% |
| 2013-12-31 | CN¥74.44 Million ≈ $10.89 Million |
-- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more